Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carbidopa-Levodopa in Dry AMD with Geographic Atrophy
NCT03451500Phase 2Terminated
- Sponsor
- Robert W. Snyder
- Start
- Jul 2018
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of levodopa in age-related macular degeneration (AMD) and geographic atrophy (GA) (3 arms), sponsored by Robert W. Snyder. Primary endpoint: Area of Geographic Atrophy at 12 months. Started Jul 2018; status: terminated.
02
Drugs
levodopa
03
Conditions
age-related macular degeneration (AMD)geographic atrophy (GA)
Beyond the preview
Go deeper on NCT03451500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03451500.